Abstract
Antiphospholipid syndrome (APS) is a thrombotic disorder associated with autoantibodies that target membrane phospholipids and phospholipid-binding proteins, which regulate coagulation. APS is usually characterized by major arterial or venous occlusions, pregnancy complications, or both. In 1992, Asherson described an unusual variant of APS termed the catastrophic antiphospholipid syndrome (also known as Asherson's syndrome), the hallmark of which is rapid multiorgan failure caused by widespread small-vessel thrombi. Empiric treatments have improved the prognosis of patients, but half still die from thrombotic diathesis, even though those who survive the acute stages frequently remain well. Given the persistently high mortality rate, efforts have been underway to facilitate early diagnosis, institute effective treatments in a timely manner and to better understand the cause (or causes) of this extreme condition in order to improve outcomes.
Key Points
-
The catastrophic antiphospholipid syndrome (CAPS; also known as Asherson's Syndrome) is a severe form of antiphospholipid syndrome
-
It is predominantly characterized by microangiopathy (small-vessel occlusions) but, in a third of patients, large arterial or venous thromboses might also occur; severe thrombocytopenia and hemolytic anemia are common
-
Because of significant clinical and pathologic overlap, it is proposed that a continuum exists between thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, the HELLP syndrome (hemolysis, elevated liver enzyme levels, low platelet count) and CAPS
-
A triggering event can be identified in 50% of reported cases of CAPS; these include infections, immunization, trauma, neoplasia or certain drugs
-
Early and aggressive multimodal treatment is critical, including parenteral anticoagulation, steroids and antibiotics (if indicated), plasma exchange, and intravenous immunoglobulin
-
Cytotoxic therapy with cyclophosphamide is often used, albeit without known benefits
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Asherson RA (1992) The catastrophic antiphospholipid syndrome J Rheumatol 19: 508–512
Lai S et al. (2005) Catastrophic antiphospholipid syndrome: a rare cause of disseminated microvascular thrombotic injury—a case report with pathological and molecular correlative studies. Pathol Int 55: 144–149
Erkan D et al. (2003) Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis 62: 530–533
Piette JC et al. (2003) The catastrophic antiphospholipid syndrome—Asherson's syndrome. Ann Med Intern 154: 195–196
Asherson RA and Cervera R. (2000) Catastrophic antiphospholipid syndrome. Curr Opin Hematol 7: 325–329
Asherson RA and Piette JC (1996) The catastrophic antiphospholipid syndrome 1996: acute multi-organ failure associated with antiphospholipid antibodies: a review of 31 patients. Lupus 5: 414–417
Asherson RA (2004) The catastrophic antiphospholipid (Asherson's) syndrome in 2004—a review. Autoimmun Rev 4: 48–54
Asherson RA and Cervera R (2003) Catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 5: 395–400
Cervera R et al. (2005) Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64: 1205–1209
Cervera R et al. (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002: 46: 1019–1027
Asherson RA et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12: 530–534
Cervera R et al. (2004) Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis 63: 1312–1317
Triplett DA and Asherson RA (2000) Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS). Am J Hematol 65: 154–159
Olguin-Ortega L et al. (2003) Neurological involvement as a poor prognostic factor in catastrophic antiphospholipid syndrome: autopsy findings in 12 cases Lupus 12: 93–98
Thuerl C et al. (2002) Imaging findings in the rare catastrophic variant of the primary antiphospholipid syndrome. Eur Radiol 12: 545–548
Sinha J et al. (2002) Bone marrow necrosis and refractory HELLP syndrome in a patient with catastrophic antiphospholipid antibody syndrome. J Rheumatol 29: 195–197
Asherson RA et al. (1998) Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77: 195–207
Westney GE and Harris EN (2002) Catastrophic antiphospholipid syndrome in the intensive care unit. Crit Care Clin 18: 805–817
Kitchens CS (2004) Thrombotic storm: when thrombosis begets thrombosis. Am J Med 104: 381–385
Blank M et al. (2004) Antiphospholipid syndrome: infectious origin. J Clin Immunol 24: 12–23
Espinosa G et al. (2004) Thrombotic microangiopathic haemolytic anemia and antiphospholipid antibodies. Ann Rheum Dis 63: 730–736
Neuwelt CM (1997) et al. Catastrophic antiphospholipid syndrome: response to repeated plasmapheresis over three years. Arthritis Rheum 40: 1534–1539
Koenig M et al. (2005) Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol 24: 166–168
Miesbach W et al. (2004) Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation. Clin Rheumatol 2: 256–261
Bucciarelli S et al. (2004) Susac's syndrome or catastrophic antiphospholipid syndrome? Lupus 13: 607–608
Tsai H-M (2004) Molecular mechanisms in thrombotic thrombocytopenic purpura. Thromb Haemost 30: 549–567
Karmochkine M et al. (1996) High prevalence of antiphospholipid antibodies in disseminated intravascular coagulation. Thromb Haemost 75: 971
Asherson RA (2005) Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and hematological characteristics of 23 patients. Ann Rheum Dis 64: 943–946
Bird et al. (1987) Disseminated intravascular coagulation: antiphospholipid antibodies, and ischemic necrosis of the extremities. Ann Rheum Dis 46: 251–255
Matsuda J et al. (2002) Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrand cleaving protease. Lupus 11: 463–464
Ozaki M et al. (2005) Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. Can J Anaesth 52: 143–147
Kwaan HC (1987) Role of fibrinolysis in thrombotic thrombocytopenic purpura. Semin Hematol 24: 101–109
Siddiqui FA and Lian EC (1992) Platelet-agglutinating protein p37 from a thrombotic thrombocytopenic purpura plasma forms complexes with platelet membrane glycoprotein IV (CD36). Biochem Int 27: 485–496
Kelton JG et al. (1996) Isolation and characterization of cysteine proteinase in thrombotic thrombocytopenic purpura. Br J Haematol 93: 421–426
Burns ER and Zucker-Franklin D (1982) Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells. Blood 60: 1030–1037
Praprotnik S et al. (2001) Anti-endothelial cell antibodies from patients with thrombotic thrombocytopenic purpura specifically activate small vessel endothelial cells. Int Immunol 13: 203–210
Mauro M et al. (2001) Role of transforming growth factor β1 in microvascular endothelial cell apoptosis associated with the thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. Am J Haematol 66: 12–22
Romani DW et al. (2003) Endothelial cell activation in thrombotic thrombocytopenic purpura (TTP). A prospective analysis. Br J Hematol 123: 522–527
Amital H et al. (2001) Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 patients. Semin Arthritis Rheum 31: 127–132
Ehresmann S et al. (2003) A novel therapeutic approach for catastrophic antiphospholipid syndrome (CAPS) when conventional therapy with anticoagulants and steroids were unsuccessful [abstract]. Ann Rheum Dis 62 (Suppl 2): ii55–59
de Groote PG et al. (1996) Protein C and other cofactors involved in the binding of phospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 5: 488–494
Bernard GR et al. (2001) Efficacy and safety of recombinant human APC for severe sepsis. N Engl J Med 344: 699–709
Burcoglu-O'Ral A et al. (2002) Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol 29: 2006–2011
Acknowledgements
The authors would like to acknowledge the members of the Catastrophic Antiphospholipid Syndrome (CAPS) Registry, including Ricard Cervera, Yehuda Shoenfeld, Jean-Charles Piette, Doruk Erkan, José Alfredo Gómez and Roger Levy, among others.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr. Merrill is a consultant for Genentech, Biogen-IDEC who are developing rituximab for use in systemic lupus erythematosus, and is actively involved in ongoing trials of this agent.
Rights and permissions
About this article
Cite this article
Merrill, J., Asherson, R. Catastrophic antiphospholipid syndrome. Nat Rev Rheumatol 2, 81–89 (2006). https://doi.org/10.1038/ncprheum0069
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0069
This article is cited by
-
Catastrophic antiphospholipid syndrome: is life-long anticoagulation therapy required?
Clinical Rheumatology (2020)
-
Perioperative Management of Patients with Inflammatory Rheumatic Diseases Undergoing Major Orthopaedic Surgery: A Practical Overview
Advances in Therapy (2018)
-
Perioperative care for patients with rheumatic diseases
Nature Reviews Rheumatology (2012)
-
The Catastrophic Antiphospholipid Syndrome in Serbia: Diagnostic and Management Problems
Clinical Reviews in Allergy & Immunology (2009)
-
Clinical and Laboratory Features of the Catastrophic Antiphospholipid Syndrome
Clinical Reviews in Allergy & Immunology (2009)